Foster W B, Tucker M M, Katzmann J A, Miller R S, Nesheim M E, Mann K G
Blood. 1983 Jun;61(6):1060-7.
BALB/c mice were immunized with human factor V. The immunogen was a mixture of procofactor (factor V) and thrombin-activated cofactor (factor Va). Spleen cells were obtained from an immunized animal and fused with NS-1 murine myeloma cells. Hybrid cell cultures were assayed for the production of antibodies to human factor V and factor Va by a solid-phase radioimmunoassay. Factor V and/or factor-Va-specific antibodies were detected in 38 of the 96 cultures assayed. The cells from 10 of these positive cultures were subcloned by limiting dilution and grown as ascites tumors in BALB/c mice. Ascitic fluids were obtained and characterized with respect to their binding interaction with human factor V and factor Va. Three hybridoma cell lines produce monoclonal antibodies that react equally well with factor V and factor Va. Another antibody reacts with both antigens, but the reactivity with factor V is better than with factor Va. An additional two antibodies react with factor Va better than factor V in the radioimmunoassay (RIA). The remaining four antibodies react exclusively with factor V. A previously described murine monoclonal antibody to human factor V (alpha HFV-1) has been used to study the peptides produced during the thrombin-catalyzed activation of human factor V. This antibody binds both factor V and factor Va, releases them at high ionic strength, and has an apparent dissociation constant for factor Va of 3 x 10(-9)M. When human factor V (mol wt 330,000) is activated by thrombin and passed over an alpha HFV-1-Sepharose affinity resin, factor Va binds and subsequently can be eluted. The eluate in 1.2 M NaCl contains two fragments of apparent mol wt 93,000 and 70,000. EDTA, which inactivates factor Va, promotes release of the mol wt 93,000 fragment from factor Va bound to the antibody. Subsequent elution with 1.2 M NaCl releases the mol wt 70,000 fragment. These observations indicate that human factor Va is a two subunit protein and that the epitope for alpha HFV-1 is on the mol wt 70,000 fragment.
用人类凝血因子V对BALB/c小鼠进行免疫。免疫原是辅因子(凝血因子V)和凝血酶激活的辅因子(凝血因子Va)的混合物。从免疫后的动物获取脾细胞,并与NS-1鼠骨髓瘤细胞融合。通过固相放射免疫测定法检测杂交细胞培养物中针对人类凝血因子V和凝血因子Va的抗体产生情况。在检测的96个培养物中,有38个检测到了凝血因子V和/或凝血因子Va特异性抗体。对其中10个阳性培养物的细胞进行有限稀释亚克隆,并在BALB/c小鼠中作为腹水瘤生长。获取腹水并对其与人凝血因子V和凝血因子Va的结合相互作用进行表征。三个杂交瘤细胞系产生的单克隆抗体与凝血因子V和凝血因子Va的反应同样良好。另一种抗体与两种抗原都反应,但与凝血因子V的反应性优于与凝血因子Va的反应性。在放射免疫测定(RIA)中,另外两种抗体与凝血因子Va的反应性优于与凝血因子V的反应性。其余四种抗体仅与凝血因子V反应。一种先前描述的针对人类凝血因子V的鼠单克隆抗体(αHFV-1)已被用于研究凝血酶催化激活人类凝血因子V过程中产生的肽段。这种抗体同时结合凝血因子V和凝血因子Va,在高离子强度下将它们释放,并且对凝血因子Va的表观解离常数为3×10⁻⁹M。当人类凝血因子V(分子量330,000)被凝血酶激活并通过αHFV-1-琼脂糖亲和树脂时,凝血因子Va会结合,随后可以被洗脱。在1.2M NaCl中的洗脱液包含两个表观分子量分别为93,000和70,000的片段。能使凝血因子Va失活的EDTA促进与抗体结合的凝血因子Va释放分子量为93,000的片段。随后用1.2M NaCl洗脱释放分子量为70,000的片段。这些观察结果表明人类凝血因子Va是一种双亚基蛋白,并且αHFV-1的表位位于分子量为70,000的片段上。